Cancer cell · 2026
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Qi, Huang Runjie, Wang Chaoye, Hu Jiajia, Nie Runcong, Jian Rui, Wang Yingnan, Wang Dongfang, Liang Chengcai, Chen Yanxing, Chen Yukun, Wu Chenyi, Zhang Jinling, Chen Jiaying, An Nan, Jin Ying, Guan Wenlong, Wang Zixian, Li Yuanfang, Sun Xiaowei, Chen Yingbo, Wang Wei, Qiu Haibo, Zhou Zhiwei, Wang Feng, Xu Rui-Hua, Yuan Shuqiang
Аннотация
Although neoadjuvant immunochemotherapy (nICT) improves gastric cancer (GC) outcomes, resistance remains a challenge, highlighting the need for better patient selection and strategies to overcome resistance. Here, we analyze 110 patients with GC before and after nICT or chemotherapy (nCT) from the NEOSUMMIT-01 trial using multi-omic sequencing followed by functional validation. We identify five tumor microenvironment ecotypes (EC1-5) linked to therapy. nICT achieves response in EC1 (T cell activation), EC2 (tertiary lymphoid structures), and EC3 (vascular normalization), but not in EC4 (extracellular matrix organization) and EC5 (immunosuppressive macrophage enrichment). Notably, nICT resistance in EC5 is mediated by the interaction between APOA1+ tumor cells and TREM2+ macrophages. Additionally, we reveal multiple biomarkers associated with nICT efficacy, including SBS19, HLA-B∗15:02, FDXR expression, and FGFR pathway activity, and provide a multi-omic stratification model for treatment response-based patient stratification. This study provides mechanistic insights into nICT in GC, informs therapeutic decisions, and reveals potential targets.